FAQ on Soligenix Inc.'s SGX302 Therapy for Psoriasis

What is SGX302 and how does it work?

SGX302 is Soligenix’s proprietary therapy for psoriasis that uses visible light to reduce inflammation and promote skin healing, aiming to mitigate risks associated with traditional treatments.

How prevalent is psoriasis in the United States?

Psoriasis affects approximately 3% of the adult population in the United States, translating to more than 7.5 million individuals, with around 600,000 adults living with undiagnosed psoriasis.

What phase of clinical trials has SGX302 undergone?

SGX302 has undergone Phase 2a clinical trials, where it was well tolerated with no significant adverse events reported, indicating its potential as a safe treatment option.

Who is developing SGX302?

SGX302 is being developed by Soligenix Inc. (NASDAQ: SNGX), a company at the forefront of creating innovative therapies for psoriasis and other conditions.

Where can I find more information about Soligenix and SGX302?

More information about Soligenix and SGX302 can be found in the company’s newsroom at https://ibn.fm/SNGX and through BioMedWire’s coverage at https://www.biomedwire.com/.

What makes SGX302 different from other psoriasis treatments?

SGX302 differentiates itself by using synthetic hypericin and visible light to target psoriasis, potentially offering a safer alternative with fewer side effects compared to traditional therapies.

How can I receive updates on SGX302 and Soligenix?

To receive SMS alerts from BioMedWire about SGX302 and Soligenix, text ‘Biotech’ to 888-902-4192 (U.S. Mobile Phones Only), or visit https://www.BioMedWire.com for more information.

What are the implications of SGX302’s success in clinical trials?

The success of SGX302 in clinical trials could provide a new, effective treatment option for millions suffering from psoriasis, significantly improving their quality of life by reducing physical and emotional symptoms.